1. Home
  2. AVDL vs NDMO Comparison

AVDL vs NDMO Comparison

Compare AVDL & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • NDMO
  • Stock Information
  • Founded
  • AVDL 2015
  • NDMO 2019
  • Country
  • AVDL Ireland
  • NDMO United States
  • Employees
  • AVDL N/A
  • NDMO N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • NDMO Trusts Except Educational Religious and Charitable
  • Sector
  • AVDL Health Care
  • NDMO Finance
  • Exchange
  • AVDL Nasdaq
  • NDMO Nasdaq
  • Market Cap
  • AVDL 764.3M
  • NDMO 627.8M
  • IPO Year
  • AVDL 1996
  • NDMO N/A
  • Fundamental
  • Price
  • AVDL $7.91
  • NDMO $10.42
  • Analyst Decision
  • AVDL Strong Buy
  • NDMO
  • Analyst Count
  • AVDL 7
  • NDMO 0
  • Target Price
  • AVDL $18.86
  • NDMO N/A
  • AVG Volume (30 Days)
  • AVDL 1.5M
  • NDMO 218.6K
  • Earning Date
  • AVDL 03-03-2025
  • NDMO 01-01-0001
  • Dividend Yield
  • AVDL N/A
  • NDMO 6.75%
  • EPS Growth
  • AVDL N/A
  • NDMO N/A
  • EPS
  • AVDL N/A
  • NDMO N/A
  • Revenue
  • AVDL $169,117,000.00
  • NDMO N/A
  • Revenue This Year
  • AVDL $51.49
  • NDMO N/A
  • Revenue Next Year
  • AVDL $32.18
  • NDMO N/A
  • P/E Ratio
  • AVDL N/A
  • NDMO N/A
  • Revenue Growth
  • AVDL 504.79
  • NDMO N/A
  • 52 Week Low
  • AVDL $7.39
  • NDMO $8.99
  • 52 Week High
  • AVDL $19.09
  • NDMO $11.24
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.28
  • NDMO 43.95
  • Support Level
  • AVDL $7.45
  • NDMO $10.40
  • Resistance Level
  • AVDL $7.97
  • NDMO $10.58
  • Average True Range (ATR)
  • AVDL 0.37
  • NDMO 0.08
  • MACD
  • AVDL -0.01
  • NDMO -0.02
  • Stochastic Oscillator
  • AVDL 33.82
  • NDMO 10.00

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest

Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.

Share on Social Networks: